Zhenming Guo

Zhenming Guo

Auto-generated profile, based on publicly available information

Zhenming Guo

Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
SBShan Bian
Shan Bian
MRMarko Repic
Marko Repic
ZGZhenming Guo
Zhenming Guo
AKAnoop Kavirayani
Anoop Kavirayani
TBThomas Burkard
Thomas Burkard
JKJürgen A. Knoblich
Jürgen A. Knoblich

29 July 2021 in EMBO Reports
Verified
Journal Article
Closed access
ZGZhenming Guo
Zhenming Guo
MCMengxia Chen
Mengxia Chen
YCYiming Chao
Yiming Chao
CCChunhai Cai
Chunhai Cai
LLLiangjie Liu
Liangjie Liu
GHguang he
guang he

20 December 2021 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
JXJiajie Xi
Jiajie Xi
YXYanxin Xu
Yanxin Xu
ZGZhenming Guo
Zhenming Guo
JLJianguo Li
Jianguo Li
YWYukang Wu
Yukang Wu
JKJiuhong Kang
Jiuhong Kang

22 August 2018 in Nature Methods
Verified
Journal Article
Open access
PDF file
SBShan Bian
Shan Bian
MRMarko Repic
Marko Repic
ZGZhenming Guo
Zhenming Guo
AKAnoop Kavirayani
Anoop Kavirayani
TBThomas Burkard
Thomas Burkard
JKJürgen A. Knoblich
Jürgen A. Knoblich
In the originally published paper, the “before” image for the afatinib condition in Fig. 6c was incorrect. Instead of an image displaying a GBM-3 neoplastic organoid before afatinib treatment, this panel showed an image from the GBM-2 control (DMSO) group before treatment. This error has now been corrected in the HTML and PDF versions of the article; the “before, afatinib” panel in Fig. 6c now shows a representative image from the indicated experiment. The color of all error bars in Fig. 6 has also been changed to black, for consistency. All statistical analysis and all conclusions presented in the article are unaffected by this error. Nevertheless, we apologize for the mistake.

1 August 2024 in Med
Verified
Journal Article
Closed access
ZGZhenming Guo
Zhenming Guo
YLYingchun Luo
Yingchun Luo
YBYan Bi
Yan Bi
LLLiangjie Liu
Liangjie Liu
YQYuan Qi
Yuan Qi
SBShan Bian
Shan Bian

8 September 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
JXJing Xu
Jing Xu
XMXiao Mao
Xiao Mao
ZLZhen Liu
Zhen Liu
NJNa Jiang
Na Jiang
XWXin E Wong
Xin E Wong
SBShan Bian
Shan Bian
Primary microcephaly, a rare congenital condition characterized by reduced brain size, occurs due to impaired neurogenesis during brain development. Through whole-exome sequencing, we identified compound heterozygous loss-of-function mutations in CENTRIN 3 ( CETN3 ) in a 5-year-old patient with primary microcephaly. As CETN3 has not been previously linked to microcephaly, we investigated its potential function in neurodevelopment in human pluripotent stem cell-derived cerebral organoids. We showed that CETN3 -knockout (KO) organoids successfully recapitulated the microcephaly phenotype of reduced size compared to the control organoids. Through transcriptomic, histological, and protein analyses, we found that CETN3 deficiency directly interferes with neuronal differentiation and reduces proliferative capacity in neural stem/progenitor cells by impairing centrosome assembly required in cell cycle progression, consequently activating apoptosis. Furthermore, our data uncovered previously undocumented indirect effects of CETN3 through interaction with RNA splicing machinery involved in brain development. These findings expand the scope of known regulatory mechanisms of CETN3 in brain development and its etiological roles in human brain malformation.